Tye1001
/ Tyercan Bio-Pharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 14, 2023
The targeting drug conjugate Tye1001 displayed its potent anti-tumor efficacy in lymphoma
(AACR 2023)
- "In our in vivo assays, the similar results were also observed in multiple other tumors such as gastric cancer and leukemia. Our findings provide a more potential druggable opportunity in the clinical applications of cancer patients and the treatment of different types of cancers."
Clinical • Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1